Apparatus for the extracorporeal treatment of blood

ABSTRACT

An apparatus for the extracorporeal treatment of blood comprising an extracorporeal blood circuit ( 2 ), a pump ( 6 ) configured to provide fluid displacement within the extracorporeal blood circuit, and a reaction chamber ( 8 ) connected to the extracorporeal blood circuit and configured to receive blood or plasma from the circuit and treat the blood or plasma. The reaction chamber comprises a protease enzyme immobilized to a support, in which the protease enzyme is specific for, and capable of irreversibly cleaving, a human C5a present in the blood or plasma, wherein the abundance of the human C5a in the treated blood or plasma is less than that in the untreated blood or plasma. The apparatus finds utility in the extracorporeal treatment of blood from patients with inflammatory conditions, especially auto-immune disease and sepsis.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of application Ser. No. 15/242,775filed on Aug. 22, 2016, which is a continuation of application Ser. No.14/314,387 filed on Jun. 25, 2014, now U.S. Pat. No. 9,422,541, whichclaims priority from European Patent Application No. 13197790.2, filedon Dec. 17, 2013. The contents of these previously filed applicationsare incorporated herein by reference in their entirety.

BACKGROUND

State-of-the-art hospital treatment for sepsis is the implementation of‘The Sepsis Six’ (PMID 21398303). These are a series of interventions tostabilize the patient, including delivery of antibiotics, microbialculture, delivery of high-flow oxygen, and fluids. To date,interventions to mitigate organ damage in sepsis have failed. Treatmentwith Drotrecogin alfa activated, a serine protease involved in switchingoff coagulation, was, until very recently, the major FDA-approvedintervention for treatment of human sepsis. However in 2011 FDAannouncing that Eli Lilly had withdrawn Xigris (Drotrecogin alfa). Onthe 8 Aug. 2012, AstraZeneca announced that a Phase IIb study testingthe efficacy of CytoFab™, an anti-TNFα polyclonal antibody fragment, fortreatment of severe sepsis and/or septic shock, did not show anysignificant improvement over placebo and AZ halted any furtherdevelopments.

Two additional treatments have been proposed based on a bloodpurification strategy with some similarity to that proposed in thisdocument. Cytosorb's IL-8 adsorption cassette is based on a porousmaterial that adsorbs the cytokine IL-8, but the technique isnon-selective, and removes other small protein components of the blood(found on the World Wide Web at cytosorbents.com/tech.htm). The secondstrategy is a specific adsorption resin removing bacterial LPS fromblood circulated through a cassette (found on the World Wide Web ataltecomedical.com/market_product.php), and is a treatment limited tosepsis caused by Gram negative bacteria.

There is a large body of evidence establishing the role of C5a insepsis. The Cell Envelope Protease ScpA targets the immuneproinflammatory mediator C5a and specifically cleaves the mediator,rendering it inactive.

It is an object of the invention to overcome at least one of theabove-referenced problems.

SUMMARY

The invention is based on a method and device for the extracorporealtreatment of inflammatory conditions in a patient, especiallyauto-immune diseases, sepsis or septicemia, that involves reacting bloodthat has been removed from a patient with a protease enzyme immobilizedto a support in which the enzyme is specific for a pro-inflammatorymediator present in the blood of the patient and is capable of cleavingthe pro-inflammatory mediator and thereby reducing the abundance ofpro-inflammatory mediator in the blood of the patient prior to thereturn of the treated blood to the patient.

In a first aspect, the invention relates to an apparatus for theextracorporeal treatment of blood comprising:

an extracorporeal blood circuit;

optionally, a pump configured to provide fluid displacement within theextracorporeal blood circuit; and

a reaction chamber connected to the extracorporeal blood circuit andconfigured to receive blood or a pro-inflammatory mediator containingblood fraction from the circuit and treat the blood or pro-inflammatorymediator containing blood fraction, characterized in that the reactionchamber comprises a protease enzyme irreversibly immobilized to asupport, in which the protease enzyme is specific for, and capable ofirreversibly cleaving, a human pro-inflammatory mediator present in theblood or plasma such that the chemoattractant capability of thepro-inflammatory mediator is reduced or preferably abrogated, whereinthe abundance of functional pro-inflammatory mediator in the treatedblood or plasma is less than that in the untreated blood or plasma.

Compared with extracorporeal treatment devices that operate on the basisof adsorption of pro-inflammatory mediators, the apparatus of theinvention has a number of advantages. Each molecule of enzyme can cleavea large number of molecules of substrate during a treatment operation;this contrasts with the adsorption process in which the ligand, oncebound to its target molecule, is unavailable for binding with furthertarget molecules. Second, the affinity antibody-based approaches of theprior art are susceptible to cross-reacting with non-target molecules,and involve significant costs in the development and generation ofsuitable antibodies. In contracts, enzymes that are specific topro-inflammatory mediators are known from the literature, and can beeasily produced using recombinant DNA technology.

Preferably, the pro-inflammatory mediator is selected from a groupconsisting of, but not limited to: C3a, C4a, C5a, IL-8, IL-6, TNFα,IL-1, or Mig. Thus, in one embodiment, the protease enzyme is capable ofcleaving a human pro-inflammatory mediator selected from a groupconsisting of, but not limited to, C3a, C4a, C5a, IL-8, IL-6, TNFα,IL-1, and Mig.

In a preferred embodiment, the invention provides an apparatus for theextracorporeal treatment of blood comprising:

an extracorporeal blood circuit;

optionally, a pump configured to provide fluid displacement within theextracorporeal blood circuit; and

a reaction chamber connected to the extracorporeal blood circuit andconfigured to receive blood or a human C5a-containing blood fractionfrom the circuit and treat the blood or human C5a-containing bloodfraction,

characterized in that the reaction chamber comprises a protease enzymeirreversibly immobilized to a support, in which the protease enzyme isspecific for, and capable of irreversibly cleaving, human C5a present inthe blood or blood fraction such that the chemoattractant capability ofthe cleaved human C5a is reduced, wherein the abundance of thefunctional human C5a in the treated blood or blood fraction is less thanthat in the untreated blood or blood fraction.

As used herein, the term “functional human C5a” should be understood tomean human C5a having chemoattractant capability as determined using thechemoattractant capability assay described below. Likewise, the term“non-functional human C5a” should be understood to mean cleaved C5aprotein that has reduced, or is devoid of, chemoattractant capability asdetermined using the chemoattractant capability assay described below.

The invention also provides an apparatus for treating human blood or apro-inflammatory mediator-containing blood fraction, the apparatuscomprising a protease enzyme irreversibly bound to a support, in whichthe protease enzyme is specific for, and capable of irreversiblycleaving, a pro-inflammatory mediator present in the blood or bloodfraction such that the chemoattractant capability of the cleaved humanpro-inflammatory mediator is reduced.

The invention also provides an apparatus for treating human blood or aC5a-containing blood fraction, the apparatus comprising a proteaseenzyme irreversibly bound to a support, in which the protease enzyme isspecific for, and capable of irreversibly cleaving, human C5a present inthe blood or blood fraction such that the chemoattractant capability ofthe cleaved human C5a is reduced.

The invention also provides a protease enzyme comprising the sequence ofA-B-C-D, in which:

A is a protease enzyme that is specific for, and capable of irreversiblycleaving, a human pro-inflammatory mediator present in the blood suchthat the chemoattractant capability of the cleaved pro-inflammatorymediator is reduced, B is a poly-lysine, poly-cysteine or poly-glutamatemotif, C is a spacer (for example a short peptide of 2 to 20 aminoacids), and D is a poly-histidine motif.

Preferably, the protease enzyme is a recombinant bacterial C5a proteasecomprising a sequence of SEQ ID NO: 3 or a functional variant thereof,typically having at least 70%, 80% or 90% sequence identity with SEQ IDNO: 3.

The term “functional variant” as applied to SEQ ID NO: 3 means aprotease that is specific for, and capable of irreversibly cleaving,human C5a such that the chemoattractant capability of the cleaved humanC5a is reduced, or preferably abrogated.

Examples functional variants of SEQ ID NO: 3 are selected from SEQ IDNO: 4 and SEQ ID NO: 5.

In one embodiment, the apparatus of the invention includes separatingmeans adapted to separate the blood into a C5a-containing fraction and anon-C5a containing fraction, wherein the reaction chamber receives theC5a-containing fraction. The separating means could be, for example, afilter configured to separate the blood or a fraction thereof into alow-molecular weight containing fraction and a second fraction, whereinthe low molecular weight containing fraction is the C5a containingfraction.

Suitably, the apparatus of the invention includes means configured torecombine the treated C5a-containing fraction (i.e. the low molecularweight fraction) with the second non-C5a containing fraction. Therecombined fractions are then returned to the patient.

In one preferred embodiment of the invention, a C-terminal of theprotease enzyme comprises a first tag and a second tag located distallyof the first tag and separated from the first tag by a spacer.Typically, the support comprises a coordinated transition metal ion andone or more functional groups. Suitably, the first tag comprises a motifcapable of covalently reacting with the one or more functional groups,and wherein the second tag comprises a motif capable of interacting withthe coordinated transition metal ion.

In this manner, the protease enzyme can be oriented with respect to thesurface such that the C-terminus of the enzyme is disposed adjacent tothe surface (this is achieved by the interaction between the second tagand the coordinated transition metal of the support surface), thusallowing the adjacent first tag to covalently bind to the functionalgroups on the surface. This will prevent unspecific binding betweenfunctional groups on the surface and lysine residues in the proteaseenzyme.

Preferably, the first tag is selected from poly-lysine, poly-glutamate,or poly-cysteine tag, and the functional groups on the surface aregroups that are capable of covalently binding with these motifs.

Suitably, the second tag comprises a poly-histidine tag or another tagcapable of interaction with a transition metal.

Preferably, the coordinated transition metal ion is selected from Ni²⁺,Co²⁺, Zn²⁺, and Cu²⁺.

Both tags can be appended onto the DNA sequence by PCR based methodsusing an oligonucleotide synthesized to contain the required sequence.

Typically, the support comprises a silica material, preferably amesoporous silica material, preferably modified monodispersed mesoporoussilicate material, and ideally a Ni²⁺-modified mesoporous silicamaterial. Other potential materials for the support include but are notlimited to methacrylates, polyacrylamides, polypyrroles andpolysaccharides.

Suitably, the support comprises a bead. Preferably, the reaction chambercomprises a column containing a multiplicity of beads.

The invention also relates to an apparatus of the invention for use in amethod for the ex-vivo treatment of blood in a mammal, typically ahuman. Preferably, the mammal has an inflammatory condition such assepsis.

The nucleic acid sequence encoding the bacterial C5a pro-protease, ScpAfrom Streptococcus pyogenes, is provided in SEQ ID NO: 1 below:

DNA sequence (SEQ ID NO: 1)GGATCCAATACTGTGACAGAAGACACTCCTGCTACCGAACAAGCCGTAGAAACCCCACAACCAACAGCGGTTTCTGAGGAAGCACCATCATCATCAAAGGAAACCAAAATCCCACAAACTCCTGGTGATGCAGAAGAAACAGTAGCAGATGACGCTAATGATCTAGCCCCTCAAGCTCCTGCTAAAACTGCTGATACACCAGCAACCTCAAAAGCGACTATTAGGGATTTGAACGACCCTTCTCAGGTCAAAACCCTGCAGGAAAAAGCAGGCAAGGGAGCTGGGACTGTTGTTGCAGTGATTGATGCTGGTTTTGATAAAAATCATGAAGCGTGGCGCTTAACAGACAAAACTAAAGCACGTTACCAATCAAAAGAAGATCTTGAAAAAGCTAAAAAAGAGCACGGTATTACCTATGGCGAGTGGGTCAATGATAAGGTTGCTTATTACCACGATTATAGTAAAGATGGTAAAACCGCTGTCGATCAAGAGCACGGCACACACGTGTCAGGGATCTTGTCAGGAAATGCTCCATCTGAAACGAAAGAACCTTACCGCCTAGAAGGTGCGATGCCTGAGGCTCAATTGCTTTTGATGCGTGTCGAAATTGTAAATGGACTAGCAGACTATGCTCGTAACTACGCTCAAGCTATCAGAGATGCTGTCAACTTGGGAGCTAAGGTGATTAATATGAGCTTTGGTAATGCTGCACTAGCTTACGCCAACCTTCCAGACGAAACCAAAAAAGCCTTTGACTATGCCAAATCAAAAGGTGTTAGCATTGTGACCTCAGCTGGTAATGATAGTAGCTTTGGGGGCAAAACCCGTCTACCTCTAGCAGATCATCCTGATTATGGGGTGGTTGGGACGCCTGCAGCGGCAGACTCAACATTGACAGTTGCTTCTTACAGCCCAGATAAACAGCTCACTGAAACTGCTACGGTCAAAACAGACGATCATCAAGCTAAAGAAATGCCTGTTCTTTCAACAAACCGTTTTGAGCCAAACAAGGCTTACGACTATGCTTATGCTAATCGTGGGATGAAAGAAGATGATTTTAAGGATGTCAAAGGCAAAATTGCCCTTATTGAACGTGGTGATATTGATTTCAAAGATAAGATTGCAAACGCTAAAAAAGCTGGTGCTGTAGGGGTCTTGATCTATGACAATCAAGACAAGGGCTTCCCGATTGAATTGCCAAATGTTGATCAGATGCCTGCGGCCTTTATCAGTCGAAAAGACGGTCTCTTATTAAAAGACAATTCTAAAAAAACCATCACCTTCAATGCGACACCTAAGGTATTGCCAACAGCAAGTGACACCAAACTAAGCCGCTTCTCAAGCTGGGGTTTGACAGCTGACGGCAATATTAAGCCAGATATTGCAGCACCCGGCCAAGATATTTTGTCATCAGTGGCTAACAACAAGTATGCCAAACTTTCTGGAACTAGTATGTCTGCGCCATTGGTAGCGGGTATCATGGGACTATTGCAAAAGCAATATGAGACACAGTATCCTGATATGACACCATCAGAGCGTCTTGATTTAGCTAAAAAAGTATTGATGAGCTCAGCAACTGCCTTATATGATGAAGATGAAAAAGCTTATTTTTCTCCTCGCCAACAAGGAGCAGGAGCAGTCGATGCTAAAAAAGCTTCAGCAGCAACGATGTATGTGACAGATAAGGACAATACCTCAAGCAAGGTTCACCTGAACAATGTTTCTGATAAATTTGAAGTAACAGTAACAGTTCACAACAAATCTGATAAACCTCAAGAGTTGTATTACCAAGCAACTGTTCAAACAGATAAAGTAGATGGAAAACACTTTGCCTTGGCTCCTAAAGCATTGTATGAGACATCATGGCAAAAAATCACAATTCCAGCCAATAGCAGCAAACAAGTCACCGTTCCAATCGATGCTAGTCGATTTAGCAAGGACTTGCTTGCCCAAATGAAAAATGGCTATTTCTTAGAAGGTTTTGTTCGTTTCAAACAAGATCCTAAAAAAGAAGAGCTTATGAGCATTCCATATATTGGTTTCCGAGGTGATTTTGGCAATCTGTCAGCCTTAGAAAAACCAATCTATGATAGCAAAGACGGTAGCAGCTACTATCATGAAGCAAATAGTGATGCCAAAGACCAATTAGATGGTGATGGATTACAGTTTTACGCTCTGAAAAATAACTTTACAGCACTTACCACAGAGTCTAACCCATGGACGATTATTAAAGCTGTCAAAGAAGGGGTTGAAAACATAGAGGATATCGAATCTTCAGAGATCACAGAAACCATTTTTGCAGGTACTTTTGCAAAACAAGACGATGATAGCCACTACTATATCCACCGTCACGCTAATGGCAAACCATATGCTGCGATCTCTCCAAATGGGGACGGTAACAGAGATTATGTCCAATTCCAAGGTACTTTCTTGCGTAATGCTAAAAACCTTGTGGCTGAAGTCTTGGACAAAGAAGGAAATGTTGTTTGGACAAGTGAGGTAACCGAGCAAGTTGTTAAAAACTACAACAATGACTTGGCAAGCACACTTGGTTCAACCCGTTTTGAAAAAACGCGTTGGGACGGTAAAGATAAAGACGGCAAAGTTGTTGTTAACGGAACCTACACCTATCGTGTCCGCTACACTCCGATTAGCTCAGGTGCAAAAGAACAACACACTGATTTTGATGTGATTGTAGACAATACGACACCTGAAGTCGCAACATCGGCAACATTCTCAACAGAAGATCGTCGTTTGACACTTGCATCTAAACCAAAAACCAGCCAACCGATTTACCGTGAGCGTATTGCTTACACTTATATGGATGAGGATCTGCCAACAACAGAGTATATTTCTCCAAATGAAGATGGTACCTTTACTCTTCCTGAAGAGGCTGAAACAATGGAAGGCGGTACTGTTCCATTGAAAATGTCAGACTTTACTTATGTTGTTGAAGATATGGCTGGTAACATCACTTATACACCAGTGACTAAGCTATTGGAGGGCCA CTCTTAA

The amino acid sequence of the bacterial C5a pro-protease, ScpA fromStreptococcus pyogenes, is provided in SEQ ID NO: 2 below:

Protein sequence (SEQ ID NO: 2)GPLGSNTVTEDTPATEQAVETPQPTAVSEEAPSSSKETKIPQTPGDAEETVADDANDLAPQAPAKTADTPATSKATIRDLNDPSQVKTLQEKASKGAGTVVAVIDAGFDKNHEAWRLTDKTKARYQSKEDLEKAKKEHGITYGEWVNDKVAYYHDYSKDGKTAVDQEHGTHVSGILSGNAPSETKEPYRLEGAMPEAQLLLMRVEIVNGLADYARNYAQAIRDAVNLGAKVINMSFGNAALAYANLPDETKKAFDYAKSKGVSIVTSAGNDSSFGGKTRLPLADHPDYGVVGTPAAADSTLTVASYSPDKQLTETATVKTDDHQAKEMPVLSTNRFEPNKAYDYAYANRGMKEDDFKDVKGKIALIERGDIDFKDKIANAKKAGAVGVLIYDNQDKGFPIELPNVDQMPAAFISRKDGLLLKDNSKKTITFNATPKVLPTASDTKLSRFSSWGLTADGNIKPDIAAPGQDILSSVANNKYAKLSGTSMSAPLVAGIMGLLQKQYETQYPDMTPSERLDLAKKVLMSSATALYDEDEKAYFSPRQQGAGAVDAKKASAATMYVTDKDNTSSKVHLNNVSDKFEVTVTVHNKSDKPQELYYQATVQTDKVDGKHFALAPKALYETSWQKITIPANSSKQVTVPIDASRFSKDLLAQMKNGYFLEGFVRFKQDPKKEELMSIPYIGFRGDFGNLSALEKPIYDSKDGSSYYHEANSDAKDQLDGDGLQFYALKNNFTALTTESNPWTIIKAVKEGVENIEDIESSEITETIFAGTFAKQDDDSHYYIHRHANGKPYAAISPNGDGNRDYVQFQGTFLRNAKNLVAEVLDKEGNVVWTSEVTEQVVKNYNNDLASTLGSTRFEKTRWDGKDKDGKVVVNGTYTYRVRYTPISSGAKEQHTDFDVIVDNTTPEVATSATFSTEDRRLTLASKPKTSQPIYRERIAYTYMDEDLPTTEYISPNEDGTFTLPEEAETMEGGTVPLKMSDFTYVVEDMAGNITYTPVTKLLEGHS

The amino acid sequence of mature bacterial C5a protease, ScpA fromStreptococcus pyogenes, is provided in SEQ ID NO: 3 below:

AEETVADDANDLAPQAPAKTADTPATSKATIRDLNDPSQVKTLQEKASKGAGTVVAVIDAGFDKNHEAWRLTDKTKARYQSKEDLEKAKKEHGITYGEWVNDKVAYYHDYSKDGKTAVDQEHGTHVSGILSGNAPSETKEPYRLEGAMPEAQLLLMRVEIVNGLADYARNYAQAIRDAVNLGAKVINMSFGNAALAYANLPDETKKAFDYAKSKGVSIVTSAGNDSSFGGKTRLPLADHPDYGVVGTPAAADSTLTVASYSPDKQLTETATVKTDDHQAKEMPVLSTNRFEPNKAYDYAYANRGMKEDDFKDVKGKIALIERGDIDFKDKIANAKKAGAVGVLIYDNQDKGFPIELPNVDQMPAAFISRKDGLLLKDNSKKTITFNATPKVLPTASDTKLSRFSSWGLTADGNIKPDIAAPGQDILSSVANNKYAKLSGTSMSAPLVAGIMGLLQKQYETQYPDMTPSERLDLAKKVLMSSATALYDEDEKAYFSPRQQGAGAVDAKKASAATMYVTDKDNTSSKVHLNNVSDKFEVTVTVHNKSDKPQELYYQATVQTDKVDGKHFALAPKALYETSWQKITIPANSSKQVTVPIDASRFSKDLLAQMKNGYFLEGFVRFKQDPKKEELMSIPYIGFRGDFGNLSALEKPIYDSKDGSSYYHEANSDAKDQLDGDGLQFYALKNNFTALTTESNPWTIIKAVKEGVENIEDIESSEITETIFAGTFAKQDDDSHYYIHRHANGKPYAAISPNGDGNRDYVQFQGTFLRNAKNLVAEVLDKEGNVVWTSEVTEQVVKNYNNDLASTLGSTRFEKTRWDGKDKDGKVVVNGTYTYRVRYTPISSGAKEQHTDFDVIVDNTTPEVATSATFSTEDRRLTLASKPKTSQPIYRERIAYTYMDEDLPTTEYISPNEDGTFTLPEEAETMEGGTVPLKMSDFTYVVEDMAGNITYTPVTKLLEGHS

The amino acid sequence of a first variant of mature bacterial C5aprotease, ScpA from Streptococcus pyogenes, is provided in SEQ ID NO: 4below:

DANDLAPQAPAKTADTPATSKATIRDLNDPSQVKTLQEKASKGAGTVVAVIDAGFDKNHEAWRLTDKTKARYQSKEDLEKAKKEHGITYGEWVNDKVAYYHDYSKDGKTAVDQEHGTHVSGILSGNAPSETKEPYRLEGAMPEAQLLLMRVEIVNGLADYARNYAQAIRDAVNLGAKVINMSFGNAALAYANLPDETKKAFDYAKSKGVSIVTSAGNDSSFGGKTRLPLADHPDYGVVGTPAAADSTLTVASYSPDKQLTETATVKTDDHQAKEMPVLSTNRFEPNKAYDYAYANRGMKEDDFKDVKGKIALIERGDIDFKDKIANAKKAGAVGVLIYDNQDKGFPIELPNVDQMPAAFISRKDGLLLKDNSKKTITFNATPKVLPTASDTKLSRFSSWGLTADGNIKPDIAAPGQDILSSVANNKYAKLSGTSMSAPLVAGIMGLLQKQYETQYPDMTPSERLDLAKKVLMSSATALYDEDEKAYFSPRQQGAGAVDAKKASAATMYVTDKDNTSSKVHLNNVSDKFEVTVTVHNKSDKPQELYYQATVQTDKVDGKHFALAPKALYETSWQKITIPANSSKQVTVPIDASRFSKDLLAQMKNGYFLEGFVRFKQDPKKEELMSIPYIGFRGDFGNLSALEKPIYDSKDGSSYYHEANSDAKDQLDGDGLQFYALKNNFTALTTESNPWTIIKAVKEGVENIEDIESSEITETIFAGTFAKQDDDSHYYIHRHANGKPYAAISPNGDGNRDYVQFQGTFLRNAKNLVAEVLDKEGNVVWTSEVTEQVVKNYNNDLASTLGSTRFEKTRWDGKDKDGKVVVNGTYTYRVRYTPISSGAKEQHTDFDVIVDNTTPEVATSATFSTEDRRLTLASKPKTSQPIYRERIAYTYMDEDLPTTEYISPNEDGTFTLPEEAETMEGGTVPLKMSDFTYVVEDMAGNITYTPVTKLLEGHS

The amino acid sequence of a second variant of mature bacterial C5aprotease, ScpA from Streptococcus pyogenes, is provided in SEQ ID NO: 5below:

KTADTPATSKATIRDLNDPSQVKTLQEKASKGAGTVVAVIDAGFDKNHEAWRLTDKTKARYQSKEDLEKAKKEHGITYGEWVNDKVAYYHDYSKDGKTAVDQEHGTHVSGILSGNAPSETKEPYRLEGAMPEAQLLLMRVEIVNGLADYARNYAQAIRDAVNLGAKVINMSFGNAALAYANLPDETKKAFDYAKSKGVSIVTSAGNDSSFGGKTRLPLADHPDYGVVGTPAAADSTLTVASYSPDKQLTETATVKTDDHQAKEMPVLSTNRFEPNKAYDYAYANRGMKEDDFKDVKGKIALIERGDIDFKDKIANAKKAGAVGVLIYDNQDKGFPIELPNVDQMPAAFISRKDGLLLKDNSKKTITFNATPKVLPTASDTKLSRFSSWGLTADGNIKPDIAAPGQDILSSVANNKYAKLSGTSMSAPLVAGIMGLLQKQYETQYPDMTPSERLDLAKKVLMSSATALYDEDEKAYFSPRQQGAGAVDAKKASAATMYVTDKDNTSSKVHLNNVSDKFEVTVTVHNKSDKPQELYYQATVQTDKVDGKHFALAPKALYETSWQKITIPANSSKQVTVPIDASRFSKDLLAQMKNGYFLEGFVRFKQDPKKEELMSIPYIGFRGDFGNLSALEKPIYDSKDGSSYYHEANSDAKDQLDGDGLQFYALKNNFTALTTESNPWTIIKAVKEGVENIEDIESSEITETIFAGTFAKQDDDSHYYIHRHANGKPYAAISPNGDGNRDYVQFQGTFLRNAKNLVAEVLDKEGNVVWTSEVTEQVVKNYNNDLASTLGSTRFEKTRWDGKDKDGKVVVNGTYTYRVRYTPISSGAKEQHTDFDVIVDNTTPEVATSATFSTEDRRLTLASKPKTSQPIYRERIAYTYMDEDLPTTEYISPNEDGTFTLPEEAETMEGGTVPLKMSDFTYVVEDMAGNIT YTPVTKLLEGHS

The proteases of SEQ ID NO:s 2, 3, 4 and 5 are all capable of cleavinghuman C5a such that the chemoattractant capability of the cleavedprotease is abrogated.

The amino acid sequence of C5a protein is provided in SEQ ID NO: 6below.

C5a protein (SEQ ID NO: 6)MLQKKIEEIAAKYKHSVVKKCCYDGACVNNDETCEQRAARISLGPRCIKAFTECCVVASQLRANISHKDMQLGR

Other proteases that are specific to, and capable of cleaving, human C5ainclude ScpB from Streptococcus agalactiae, and functional variantsthereof (Brown et al). Examples of protease enzymes capable ofspecifically cleaving IL-8 include ScpC from Streptococcus pyogenes,SpyCEP from Streptococcus agalactiae and functional variants thereof(Fritzer et al, Kaur et al, Zinkernagel et al, Sjolinder et al, andHidalgo et al)

Examples of protease enzymes capable of specifically cleaving IL-6include a published Pseudomonas enzyme which degrades it completely(Matheson et al). Also gingipains K and R seem to have degradingactivity against several mediators, but lack specificity required.

Suitably, the apparatus further comprising means of separating wholeblood into a plasma fraction and a cellular fraction, and means forrecombining the cellular fraction with the treated plasma fraction. In aseparation process, the plasma in the patient's blood is typicallysegregated from its remaining constituents. The separated plasma ismixed with an acetate buffer saturated with heparin. This lowers theplasma's degree of acidity (pH value) to 5.12, causing the LDLcholesterol, Lp(a) and fibrinogen to drop selectively out of the plasma.Together with the heparin additive, the separated constituents forminsoluble precipitates which can be removed from the plasma in a singlefiltration stage. Unused surplus heparin is held back in a separateadsorber, and bicarbonate ultrafiltration is used to restore thepurified plasma to the physiologically acceptable level. The selectivelytreated, purified plasma is then remixed with the remaining bloodconstituents and supplied back to the patient. During H.E.L.P.apheresis, these four steps (plasma separation, precipitation withsubsequent filtration, heparin adsorption and ultrafiltration) areperformed by a single device, the PLASMAT Futura. Examples of devicescapable of separating whole blood into a plasma fraction and a cellularfraction in extracorporeal blood circuits are known to the personskilled in the art, and include plasmaphoresis equipment (for example BBraun PLASMAT Futura) and hemodialysis equipment (for example GambroPHEONIX found on the World Wide Web atgambro.com/en/global/Products/Hemodialysis/Monitors/Phoenix-dialysis-system/).

Typically, the reaction chamber comprises a column comprising beads inwhich the enzyme is immobilized to the beads. Alternatively, thereaction chamber may comprise a cartridge.

In a further aspect, the invention relates to a method for the treatmentor prevention of an inflammatory condition in a human comprising thesteps of reacting blood that has been removed from the patient, or apro-inflammatory mediator containing fraction of the blood, with aprotease enzyme immobilized to a support, in which the protease enzymeis specific for, and capable of irreversibly cleaving, a humanpro-inflammatory mediator present in the blood or fraction such that thechemoattractant capability of the pro-inflammatory mediator is reducedor preferably abrogated, wherein the abundance of functionalpro-inflammatory mediator in the treated blood or fraction is less thanthat in the untreated blood or fraction.

Typically, the human pro-inflammatory mediator is selected from thegroup consisting of, but not limited to, C3a, C4a, C5a, IL-8, IL-6,TNFα, IL-1, and Mig.

In a further aspect, the invention relates to a method for the treatmentor prevention of an inflammatory condition in a human comprising thesteps of reacting blood that has been removed from the patient, or apro-inflammatory mediator containing fraction of the blood, with aprotease enzyme immobilized to a support, in which the protease enzymeis specific for, and capable of irreversibly cleaving, human C5a presentin the blood or fraction such that the chemoattractant capability of thecleaved human C5a is reduced or preferably abrogated, wherein theabundance of functional C5a in the treated blood or fraction is lessthan that in the untreated blood or plasma.

Suitably, the method includes the steps of separating the blood into aplasma fraction and a cellular fraction, treating the plasma fraction,and then recombining the cellular fraction with the treated plasmafraction prior to returning the blood to the patient.

Alternatively, or in addition, the method includes the steps ofseparating the blood into a C5a containing fraction (for example, a lowmolecular weight fraction) fraction and a second fraction, treating theC5a containing fraction, and then recombining the second fraction withthe treated C5a containing fraction prior to returning the blood to thepatient.

Typically, the method is carried out in a continuous fashion using anextracorporeal blood circuit.

Suitably, the protease enzyme is a recombinant protein.

The invention also relates to a support and a recombinant proteaseenzyme immobilized to the support, in which the recombinant proteaseenzyme comprises a C-terminal poly-histidine tag and a C-terminalpoly-lysine tag, and in which the recombinant protease enzyme comprisesa protease that is specific for, and capable of irreversibly cleaving, ahuman pro-inflammatory mediator present in the blood or plasma.

In this specification, the term “extracorporeal blood circuit” should beunderstood to mean an arrangement of conduits capable of removing bloodfrom the body for treatment outside of the body and returning the thustreated blood to the body.

In this specification, the term “reaction chamber” should be understoodto mean a chamber adapted to receive blood or plasma from theextracorporeal blood circuit and allow contact between the blood orplasma and protease enzyme that is immobilized to a support within thereaction chamber.

In this specification, the term “plasma” should be understood to meanblood from which cells have been fully or partially removed.

In this specification, the term “pro-inflammatory mediator” should beunderstood to mean a host proteinaceous entity produced in theauto-immune or sepsis response which stimulates other components of thehost immune system, in particular causing migration or stimulation ofleukocytes of any class and progenitor forms of these cells. Specificexamples of pro-inflammatory mediators specific to the humaninflammatory response include C3a, C4a, C5a, IL-8, IL-6, TNFα, IL-1, andMig.

In the specification, the term “protease enzyme that is specific for ahuman pro-inflammatory mediator” should be understood to mean an enzymewith the capacity to selectively, or ideally solely, break peptide bondsof pro-inflammatory mediators of human origin by hydrolysis. Theprotease may also be derived from the parent protease, and modified toinclude a functionalization group, for example one or more of apoly-histidine, poly-lysine, or poly-glutamic acid tag.

In this specification, the term “functional variant thereof” as appliedto a specific protease enzyme should be understood to mean a variant ofthe protease enzyme that retains the ability to specifically bind andirreversibly cleave the target pro-inflammatory mediator such that thechemoattractant activity of the cleaved pro-inflammatory mediator isreduced or abrogated. Thus, for example, a functional variant of ScpAfrom Streptococcus pyogenes includes variant ScpA proteases that havethe ability to specifically bind and irreversibly cleave the human C5aprotein such that the chemoattractant capability of the cleaved proteaseis reduced or abrogated, and include ScpA proteases from Streptococcuspyogenes (SEQ ID NO:2, 3, 4, 5) and other Streptococcal species. Theterm “variant” should be understood to mean proteins or polypeptidesthat have at least 70% sequence homology with the reference protease,and that are altered in respect of one or more amino acid residues.Preferably such alterations involve the insertion, addition, deletionand/or substitution of 20, 10, 5 or fewer amino acids, more preferablyof 4 or fewer, even more preferably of 3 or fewer, most preferably of 1or 2 amino acids only. Insertion, addition, and substitution withnatural and modified amino acids is envisaged. The variant may haveconservative amino acid changes, wherein the amino acid being introducedis similar structurally, chemically, or functionally to that beingsubstituted. Typically, proteins which have been altered by substitutionor deletion of catalytically-important residues will be excluded fromthe term “variant”. For any given protease enzyme, details of suchcatalytically-important residues will be well known to those skilled inthe art. Generally, the variant will have at least 70% amino acidsequence homology, preferably at least 80% sequence homology, morepreferably at least 90% sequence homology, and ideally at least 95%,96%, 97%, 98% or 99% sequence homology with the reference protease. Inthis context, sequence homology comprises both sequence identity andsimilarity, i.e. a polypeptide sequence that shares 90% amino acidhomology with wild-type bacterial mature C5a peptidase is one in whichany 90% of aligned residues are either identical to, or conservativesubstitutions of, the corresponding residues in wild-type bacterial C5apeptidase. Substitution may be conservative or non-conservativesubstitution, and may involve use of natural amino acids or amino acidanalogues.

The term “variant” is also intended to include chemical derivatives of aprotease, i.e. where one or more residues of a protease is chemicallyderivatized by reaction of a functional side group. Also included withinthe term variant are protease molecules in which naturally occurringamino acid residues are replaced with amino acid analogues.

Proteins and polypeptides (including variants and fragments thereof) ofand for use in the invention may be generated wholly or partly bychemical synthesis or by expression from nucleic acid. The proteins andpeptides of and for use in the present invention can be readily preparedaccording to well-established, standard liquid or, preferably,solid-phase peptide synthesis methods known in the art (see, forexample, J. M. Stewart et al).

In this specification, the term “inflammatory condition” means acondition in which the host mounts a response to an assault. Examples ofimflammatory conditions include chronic or acute inflammatory conditionsincluding sepsis, septic shock, systemic inflammatory response syndrome,multiple organ dysfunction syndrome, hyper-reactive airway disease,allergic reaction.

In a different aspect, the invention provides a method of attaching amolecule comprising a polyaminoacid sequence to a surface, in which theC-terminal of the protease enzyme comprises a first tag and a second taglocated distally of the first tag and separated from the first tag by aspacer, and in which the support comprises a coordinated transitionmetal ion and one or more functional groups, and in which the first tagcomprises a motif capable of covalently reacting with the one orfunctional groups, and wherein the second tag comprises a motif capableof interacting with the coordinated transition metal ion, the methodcomprising the step of reacting the molecule comprising a polyaminoacidsequence with the surface.

BRIEF DESCRIPTION OF THE DRAWINGS

The invention description below refers to the accompanying drawings, ofwhich:

FIG. 1 is a Diagrammatic representation of blood purifying invention.

The diagram shows the components and blood flow route envisaged for theimplementation of the invention. Blood is removed from the patient andfractionated into a high protein plasma fraction and a high blood cellfraction. The former is passed over the active material (immobilizedenzyme) in the reaction chamber and then recombined with the latterbefore return to the patient. Components of the invention are labeled: 1the overall invention, 2 the extracorporeal blood purification device, 3blood withdrawal line, 4 patient arm, 5 blood return line, 6 pumpingsystem, 7 blood separator, 8 reaction chamber, 9 cartridge housing bloodseparation chambers, 10 a and 10 b blood separation chambers, 11biocompatible size restrictive semi-permeable membrane, 12 linedelivering protein rich plasma to reaction chamber, 13 line deliveringblood cell rich fraction to mixing chamber, 14 line delivering treatedplasma to mixing chamber, 15 mixing chamber for blood reconstitution, 16vessel housing active component of reaction chamber, 17 reactivematerial comprising immobilized enzyme irreversibly coupled to solidsupport material.

FIG. 2a shows SDS-PAGE analysis of C5a untreated (−) and treated (+)with ScpA; and

FIG. 2b shows the scissile bond in the C5a sequence confirmed by MassSpec analysis of C5a cleaved with ScpA.

DETAILED DESCRIPTION

Referring to FIG. 1, there is provided an apparatus for theextracorporeal treatment of blood according to the invention, andindicated generally by the reference numeral 1. The apparatus 1comprises an extracorporeal blood circuit 2, having a feed line 3 forwithdrawing blood from a patients arm 4 for treatment and a return line5 for returning treated blood to the patient, and an adjustable pump 6provided in the feed line for providing blood displacement within theblood circuit 2.

The apparatus also includes a blood separator 7 and a reaction chamber 8in the circuit 2, the separator 7 being provided upstream of thereaction chamber 8. The separator comprises a cartridge 9 having twochambers 10 a and 10 b separated by a semi-permeable membrane 11 adaptedto allow separation of blood proteins from blood cells. The whole bloodpasses from the patient to the first chamber 10 a, where proteins inblood plasma pass into the second chamber 10 b forming a protein richplasma fraction in the second chamber and leaving blood cells in thefirst chamber 10 a. A tube 12 is provided to transfer the thus-formedprotein rich fraction plasma from the second chamber 10 b to thereaction chamber 8 where it is treated. A further tube 13 is provided totransfer the cell rich fraction from the first chamber 10 a to re-joinwith treated plasma distally of the reaction chamber 8 at a mixingchamber 15 where the two fractions are mixed prior to being returned tothe patient via the whole blood return line 5.

The reaction chamber comprises a cylindrical vessel 16 filled withfunctionalized support material 17 containing the immobilized enzyme,thereby providing a large surface area for the treatment of the incomingplasma. The tube 12 feeds into a top of the cylindrical vessel 16, andthe plasma filters through the cylinder before exiting the vesselthrough a tube 14.

Mesoporous silica (MPS) materials (including but not limited to MCM,SBA, MCF and PMO type materials) are prepared using a templatedsynthesis method. Ideally these particles will be monodispersed innature. The particles will have a specific particle size in the range of0.1-50 μm, contain nanopores with a final internal diameter in the range8-12 nm and have a high surface area 300-800 m²g⁻¹.

The surface characteristics of the silica nanocarriers will be modifiedwith a range of functional groups (e.g. —NH2, —COOH, —SH) directlyduring synthesis of the material, or by post synthesis grafting tofacilitate covalent coupling (through the poly-Gluamate or poly-Lysineor Cysteine residues respectively) of the enzyme to the surface afterorientation specific adsorption.

The Ni²⁺-modified MPS will be prepared by attachment of3-iodo-trimethoxypropylsilane to the silicate surface followed byreaction with cyclam and incorporation of the metal ion. This is togenerate immobilization of the protease in a controlled orientation.

In use, the extracorporeal blood circuit is connected to a patient,generally an arm of a patient, and the pump is actuated to withdrawblood from the patient and pump it through the circuit. The whole bloodfrom the patient enters the separator 7 and is separated under pressureinto the two fractions. The plasma fraction is pumped from the secondchamber 10 b to the reaction chamber 8 where the blood percolatesthrough the functionalized cassette bed 17. In the reaction chamber,mediator in the plasma binds to the protease enzyme that is immobilizedto the support material, and is cleaved into an inactive form that isreleased back into the plasma leaving the immobilized enzyme free foranother reaction. As a result of the plasma passing through the reactionchamber, the concentration of functional mediator in the plasma issignificantly reduced. The thus treated plasma is then pumped to themixing chamber 15 where it rejoins with the cell rich fraction to formwhole blood that is significantly depleted of active mediator protein.The whole blood is returned to the patient via the return line 5.

It will be appreciated that the use of a separator to filter the bloodprior to treatment is optional, and that the treatment of whole blood inthe reaction chamber forms part of the invention.

Experimental

Materials and Methods

C5a Peptidase Activity Assays

Recombinant C5a was produced as an N-term His-tagged fusion (HT-C5a) inaccordance with the method of Toth et al., and chemoattractant activitywas verified in an under-agarose migration assay (data not shown). TheC5a-ase activity of ScpA was demonstrated in reactions consisting of 42nM ScpA with 37 μM HT-C5a, in 50 mM Tris/HCl (pH 7.5), 100 mM NaCl, and5 mM CaCl₂ for 30 min at 20° C. The observed C5a-ase activity wasindependent of the presence of Complete Mini EDTAfree inhibitor cocktail(Roche). Matrix-assisted laser desorption ionization time-of-flight massspectrometry analysis of cleaved HT-C5a was performed.

Results

The activity assay showed that the ScpA cleaved C5a at a single site(FIG. 2a ). MS analysis indicated a loss of 830 Da, consistent with theremoval of seven residues from the C terminal (FIG. 2b ) which removeschemoattractant capabilities.

The invention is not limited to the embodiments hereinbefore describedwhich may be varied in construction and detail without departing fromthe spirit of the invention.

REFERENCES

Brown C K, Gu Z Y, Matsuka Y V, Purushothaman S S, Winter L A, Cleary PP, Olmsted S B, Ohlendorf D H, Earhart C A. Structure of thestreptococcal cell wall C5a peptidase. Proc Natl Acad Sci USA. 2005 Dec.20; 102(51):18391-6. Epub 2005 Dec. 12. PubMed PMID: 16344483; PubMedCentral PMCID: PMC1317908.

Fritzer A, Noiges B, Schweiger D, Rek A, Kungl A J, von Gabain A, NagyE, Meinke A L. Chemokine degradation by the Group A streptococcal serineproteinase ScpC can be reconstituted in vitro and requires two separatedomains. Biochem J. 2009 Aug. 27; 422(3):533-42. doi:10.1042/BJ20090278. PubMed PMID: 19552626.

Kaur S J, Nerlich A, Bergmann S, Rohde M, Fulde M, Zähner D, Hanski E,Zinkernagel A, Nizet V, Chhatwal G S, Talay S R. The CXCchemokine-degrading protease SpyCep of Streptococcus pyogenes promotesits uptake into endothelial cells. J Biol Chem. 2010 Sep. 3;285(36):27798-805. doi: 10.1074/jbc.M109.098053. Epub 2010 Jun. 18.PubMed PMID: 20562101; PubMed Central PMCID: PMC2934647.

Zinkernagel A S, Timmer A M, Pence M A, Locke J B, Buchanan J T, TurnerC E, Mishalian I, Sriskandan S, Hanski E, Nizet V. The IL-8 proteaseSpyCEP/ScpC of group A Streptococcus promotes resistance to neutrophilkilling. Cell Host Microbe. 2008 Aug. 14; 4(2):170-8. doi:10.1016/j.chom.2008.07.002. PubMed PMID: 18692776; PubMed Central PMCID:PMC2631432.

Sjölinder H, Lövkvist L, Plant L, Eriksson J, Aro H, Jones A, Jonsson AB. The ScpC protease of Streptococcus pyogenes affects the outcome ofsepsis in a murine model. Infect Immun. 2008 September; 76(9):3959-66.doi: 10.1128/IAI.00128-08. Epub 2008 Jun. 23. PubMed PMID: 18573900;PubMed Central PMCID: PMC2519448.

Hidalgo-Grass C, Mishalian I, Dan-Goor M, Belotserkovsky I, Eran Y,Nizet V, Peled A, Hanski E. A streptococcal protease that degrades CXCchemokines and impairs bacterial clearance from infected tissues. EMBOJ. 2006 Oct. 4; 25(19):4628-37. Epub 2006 Sep. 14. PubMed PMID:16977314; PubMed Central PMCID: PMC1589981.

Matheson N R, Potempa J, Travis J. Interaction of a novel form ofPseudomonas aeruginosa alkaline protease (aeruginolysin) withinterleukin-6 and interleukin-8. Biol Chem. 2006 July; 387(7):911-5.PubMed PMID: 16913841.

J. M. Stewart and J. D. Young, Solid Phase Peptide Synthesis, 2ndedition, Pierce Chemical Company, Rockford, Ill. (1984), in M. Bodanzskyand A. Bodanzsky, The Practice of Peptide Synthesis, Springer Verlag,New York (1984).

Toth, M. J., Huwyler, L., Boyar, W. C., Braunwalder, A. F., Yarwood, D.,Hadala, J., Haston, W. O., Sills, M. A., Seligmann, B., Galakatos, N.The pharmacophore of the human C5a anaphylatoxin. Protein Sci.3:1159-1168, 1994.

1. A method for the extracorporeal treatment of blood, the methodcomprising removing blood or a blood fraction from a patient andreacting the blood or blood fraction with a protease enzyme that isspecific for and capable of irreversibly cleaving functional C5a,thereby reducing an abundance of functional C5a in the blood or bloodfraction, wherein the protease enzyme is immobilised to a support. 2.The method of claim 1, wherein the protease enzyme is a recombinantbacterial C5a protease comprising SEQ ID NO. 3, or a functional variantthereof having at least 90% sequence identity with SEQ ID NO:
 3. 3. Themethod of claim 2, wherein the functional variant of SEQ ID NO: 3 is SEQID NO: 4 or SEQ ID NO:
 5. 4. The method of claim 1, wherein the reactingstep is carried out with an apparatus comprising: an extracorporealblood circuit; a pump configured to provide fluid displacement with theextracorporeal blood circuit; and a reaction chamber connected to theextracorporeal blood circuit, the reaction chamber configured to receivethe blood or blood fraction from the extracorporeal blood circuit and totreat the blood or blood fraction, wherein the reaction chamber containsthe protease enzyme immobilised to the support.
 5. The method of claim4, wherein the protease enzyme is a recombinant bacterial C5a proteasecomprising SEQ ID NO. 3, or a functional variant thereof having at least90% sequence identity with SEQ ID NO:
 3. 6. The method of claim 5,wherein the functional variant of SEQ ID NO: 3 is SEQ ID NO: 4 or SEQ IDNO:
 5. 7. The method of claim 4, wherein the apparatus further comprisesseparating means adapted to separate the blood or blood fraction into aC5a-containing fraction and a non-C5a containing fraction, wherein thereaction chamber receives the C5a-containing fraction.
 8. The method ofclaim 7, wherein the protease enzyme is a recombinant bacterial C5aprotease comprising SEQ ID NO. 3, or a functional variant thereof havingat least 90% sequence identity with SEQ ID NO:
 3. 9. The method of claim8, wherein the functional variant of SEQ ID NO: 3 is SEQ ID NO: 4 or SEQID NO:
 5. 10. The method of claim 7, wherein the apparatus furthercomprises means configured to recombine the treated C5a-containingfraction with the non-C5a containing fraction.
 11. The method of claim1, wherein the support includes a coordinated transition metal ion andone or more functional groups; the C-terminus of the protease enzymecomprises a first tag and a second tag located distally of the firsttag, the second tag being separated from the first tag by a spacer; thefirst tag comprises a motif capable of covalently reacting with the oneor more functional groups; and the second tag comprises a motif capableof interacting with the coordinated transition metal ion.
 12. The methodof claim 11, wherein the first tag is poly-lysine, poly-glutamate, orpoly-cysteine, and the second tag is poly-histidine.
 13. The method ofclaim 12, wherein the protease enzyme is a recombinant bacterial C5aprotease comprising SEQ ID NO. 3, SEQ ID NO: 4, or SEQ ID NO:
 5. 14. Themethod of claim 1, wherein the support includes a silica material, amethacrylate, a polyacrylamide, a polypyrrole, or a polysaccharide. 15.The method of claim 14, wherein the silica material is selected from thegroup consisting of mesoporous silica, a monodispersed mesoporoussilicate, and a Ni2+-modified mesoporous silica.
 16. The method of claim1, wherein the support comprises a multiplicity of beads and theprotease enzyme is irreversibly immobilized to a surface of the beads.17. A method for treating sepsis, the method comprising removing bloodor a blood fraction from a patient having sepsis and reacting the bloodor blood fraction with a protease enzyme that is specific for andcapable of irreversibly cleaving functional C5a, thereby reducing anabundance of functional C5a in the blood or blood fraction, wherein theprotease enzyme is immobilised to a support.
 18. The method of claim 17,wherein the protease enzyme is a recombinant bacterial C5a proteasecomprising SEQ ID NO. 3, SEQ ID NO: 4, or SEQ ID NO:
 5. 19. A method fortreating an inflammatory condition in a human, the method comprisingremoving blood or a blood fraction from a patient having an inflammatorycondition and reacting the blood or blood fraction with a proteaseenzyme that is specific for and capable of irreversibly cleavingfunctional C5a, thereby reducing an abundance of functional C5a in theblood or blood fraction, wherein the protease enzyme is immobilised to asupport.
 20. The method of claim 19, wherein the protease enzyme is arecombinant bacterial C5a protease comprising SEQ ID NO. 3, SEQ ID NO:4, or SEQ ID NO: 5.